Latus Bio

Executive Summary

Latus Bio is a private gene therapy company leveraging a high-throughput screening platform to engineer next-generation AAV capsids for precise delivery to central nervous system (CNS) tissues. Founded in 2020 and headquartered in San Diego, the company aims to overcome key limitations of traditional AAV vectors, such as off-target effects and suboptimal transduction, by identifying capsids with enhanced tropism and reduced immunogenicity. Their approach holds potential to transform the treatment landscape for CNS disorders, including neurodegenerative diseases, by enabling safer and more effective gene therapies that target specific cell populations with minimal systemic exposure. Latus’ proprietary technology is built upon extensive screening of capsid libraries, which may yield candidates with superior blood-brain barrier penetration and neuronal specificity. Currently operating at a preclinical stage, Latus Bio is focused on advancing its lead programs toward IND-enabling studies. The company’s innovative platform could address significant unmet needs in CNS gene therapy, where delivery challenges have historically hindered clinical progress. While specific pipeline details remain undisclosed, Latus’ technology has attracted interest from the biopharma community, reflected in its presence on biotech databases. With a strong scientific foundation and a clear focus on precision delivery, Latus Bio is poised to generate meaningful data in the near term, potentially positioning itself for partnerships or further investment as it moves toward clinical development.

Upcoming Catalysts (preview)

• Q2 2027IND submission for lead CNS gene therapy candidate55% success
• Q4 2026Presentation of preclinical proof-of-concept data at a major conference80% success
• Q2 2027Strategic partnership for capsid technology licensing or co-development50% success